322 related articles for article (PubMed ID: 10572233)
41. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Lamb HM; Adkins JC
Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
[TBL] [Abstract][Full Text] [Related]
42. [Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Junker A; Wiedemann GJ; Possinger K
MMW Fortschr Med; 2002 Jan; 144(5):46-8. PubMed ID: 11883037
[TBL] [Abstract][Full Text] [Related]
43. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
Miller WR; Dixon JM
Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
[TBL] [Abstract][Full Text] [Related]
44. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
Harper-Wynne C; Coombes RC
Eur J Cancer; 1999 May; 35(5):744-6. PubMed ID: 10505035
[TBL] [Abstract][Full Text] [Related]
45. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
[TBL] [Abstract][Full Text] [Related]
46. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
[TBL] [Abstract][Full Text] [Related]
47. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Michaud LB; Buzdar AU
Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
[TBL] [Abstract][Full Text] [Related]
48. Aromatase inhibitors and their application in breast cancer treatment*.
Brodie AM; Njar VC
Steroids; 2000 Apr; 65(4):171-9. PubMed ID: 10713305
[TBL] [Abstract][Full Text] [Related]
49. [Aromatase inhibitors in the treatment of breast cancer].
Perey L
Rev Med Suisse Romande; 2000 Jun; 120(6):495-500. PubMed ID: 11014093
[No Abstract] [Full Text] [Related]
50. Aromatase inhibitors: a dose-response effect?
Smith IE
Endocr Relat Cancer; 1999 Jun; 6(2):245-9. PubMed ID: 10731116
[No Abstract] [Full Text] [Related]
51. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
Goss PE; Strasser K
Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
[TBL] [Abstract][Full Text] [Related]
52. Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
Higa GM; alKhouri N
Am J Health Syst Pharm; 1998 Mar; 55(5):445-52. PubMed ID: 9522927
[TBL] [Abstract][Full Text] [Related]
53. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
54. Local endocrine effects of aromatase inhibitors within the breast.
Miller WR; Dixon JM
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):93-102. PubMed ID: 11850212
[TBL] [Abstract][Full Text] [Related]
55. [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].
Gershanovich M; Chaudri Kh; Campos D; Lurie H; Bonaventura A; Jeffrey M; Buzzi F; Bodrogi I; Ludwig H; Reichard P; O'Higgins NO; Romieu G; Friedrich P; Lassus M
Vopr Onkol; 1999; 45(4):361-8. PubMed ID: 10532092
[TBL] [Abstract][Full Text] [Related]
56. Vorozole.
Wiseman LR; Spencer CM
Drugs Aging; 1997 Sep; 11(3):245-50; discussion 251-2. PubMed ID: 9303282
[TBL] [Abstract][Full Text] [Related]
57. [The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Porpiglia M; Genta F; Vicelli R; De Nicola B; Ferraris F; Piccinno R; Benedetto C
Minerva Ginecol; 2002 Apr; 54(2):115-31. PubMed ID: 12032450
[TBL] [Abstract][Full Text] [Related]
58. New aromatase inhibitors for breast cancer.
Drug Ther Bull; 1997 Jul; 35(7):55-6. PubMed ID: 9282426
[TBL] [Abstract][Full Text] [Related]
59. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
60. [Aromatase inhibitors for treatment of advanced breast cancers].
Sonoo H
Nihon Rinsho; 2000 Apr; 58 Suppl():322-7. PubMed ID: 11026013
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
